Silexion Therapeutics Corp (NASDAQ:SLXN) Short Interest Update

Silexion Therapeutics Corp (NASDAQ:SLXN) was the recipient of a significant decline in short interest during the month of December. As of December 31st, there was short interest totaling 47,547 shares, a decline of 39.8% from the December 15th total of 78,920 shares. Based on an average daily volume of 57,964 shares, the short-interest ratio is currently 0.8 days. Currently, 1.6% of the shares of the company are short sold. Currently, 1.6% of the shares of the company are short sold. Based on an average daily volume of 57,964 shares, the short-interest ratio is currently 0.8 days.

Analysts Set New Price Targets

SLXN has been the subject of several research analyst reports. Zacks Research raised shares of Silexion Therapeutics to a “hold” rating in a report on Tuesday, December 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Silexion Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen cut Silexion Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. Finally, Litchfield Hills Research started coverage on Silexion Therapeutics in a research note on Monday, December 15th. They issued a “buy” rating for the company. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $75.00.

Silexion Therapeutics Stock Down 7.0%

Shares of NASDAQ SLXN traded down $0.17 during midday trading on Friday, reaching $2.27. The company’s stock had a trading volume of 36,498 shares, compared to its average volume of 55,522. The company has a quick ratio of 3.97, a current ratio of 3.97 and a debt-to-equity ratio of 0.22. The business’s 50 day moving average price is $2.50 and its two-hundred day moving average price is $5.39. Silexion Therapeutics has a fifty-two week low of $1.65 and a fifty-two week high of $51.75.

Silexion Therapeutics (NASDAQ:SLXN) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($2.88) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.40) by $0.52.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.